Iron Supplementation Contraindication in Thalassemia

Introduction to Thalassemia Management

• The American Heart Association recommends that iron supplementation is contraindicated in patients with thalassemia due to the inherent risk of iron overload from chronic transfusions and increased gastrointestinal iron absorption 1, 2

Mechanisms of Iron Overload

• Transfusion-dependent thalassemia major patients accumulate approximately 200 mg of iron per unit of transfused blood, combined with mildly increased gastrointestinal iron uptake related to hepcidin suppression 2

Organ Toxicity from Iron Overload

• Cardiac complications from myocardial siderosis are among the leading causes of death in thalassemia patients, with iron-induced cardiomyopathy historically causing death in the second decade of life before effective chelation became available 1
• Iron that is not saturated by transferrin becomes a toxic agent that generates hydroxyl and oxygen radicals, causing lipid peroxidation and damage to cell membranes, proteins, and DNA 3

The Role of Iron Chelation Therapy

• Iron chelation is the cornerstone of therapy in thalassemia, not iron supplementation, as recommended by the American College of Cardiology 1, 2

Monitoring Iron Burden

• Serum ferritin levels should be monitored, with goals of maintaining levels less than 1000-2500 mcg/L depending on clinical context, as suggested by the National Comprehensive Cancer Network 3, 4
• Cardiac MRI T2* and liver iron concentration by MRI are the gold standards for assessing organ-specific iron burden, according to the National Comprehensive Cancer Network 3

Critical Pitfall to Avoid

• Never supplement iron in thalassemia patients based on low hemoglobin alone, as the anemia in thalassemia is due to ineffective erythropoiesis and hemoglobin production defects, not iron deficiency, as stated by the American Heart Association 2, 5

Special Consideration: Vitamin C

• Avoid vitamin C supplementation in iron-overloaded thalassemia patients, as it can mobilize iron from reticuloendothelial stores, increase iron availability, and accelerate cardiac deterioration, as warned by the European Association for the Study of the Liver 6, 7

Transfusion Goals Without Iron Supplementation

• Maintain pre-transfusion hemoglobin levels of 9-10 g/dL and post-transfusion levels of 13-14 g/dL to suppress ineffective erythropoiesis while minimizing iron loading, as recommended by the American Heart Association 2, 5
• The use of erythropoietin for anemia is not advised in thalassemia patients, according to the American Society of Hematology 8, 9